The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Human epidermal growth factor receptor-2 (HER2) and neu are the human and rodent homologues of an oncogenic growth factor receptor that were identified and named independently in the early 1980s from rodent and human models, but soon found to be homologues of each other (Slamon et al., 1987).”
BackgroundThe protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“Readers are referred to several recent excellent reviews of HER family signaling and functions (Mendelsohn and Baselga, 2000; Olayioye et al., 2000; Prenzel et al., 2001; Yarden and Sliwkowski, 2001; Barnes and Kumar, 2004).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 2×
“…overexpression leads to increased expression of hypoxia-inducible factor 1a (HIF-1a) through Akt leading to increased expression of vascular endothelial growth factor (VEGF) and increased surface expression of fibronectin receptors (Laughner et al., 2001; Li et al., 2005; Spangenberg et al., 2006).”
BackgroundGuy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., & Derynck, R. (1995) · Nature · doi:10.1038/376337a0 · Cited by 1,039
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Strain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor
Sibilia, M., & Wagner, E. F. (1995) · Science · doi:10.1126/science.7618085 · Cited by 1,002
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944 · cited 2×
“Readers are referred to a number of excellent recent reviews of this topic ((Testa and Bellacosa, 2001; Vivanco and Sawyers, 2002; Luo et al., 2003; Paez and Sellers, 2003) and the entire Oncogene vol. 24; issue 50 (11/14/2005)).”
BackgroundSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802 · cited 1×
“Somatic mutations within the HER2 kinase domain have been described in a small subset of lung cancers, predominantly in Asian populations, and very rarely in gastric, colorectal and breast cancers (Figure 1, region D) (Stephens et al., 2004; Shigematsu et al., 2005; Lee et al., 2006).”
BackgroundAkiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
Shih, C., Padhy, L. C., Murray, M., & Weinberg, R. A. (1981) · Nature · doi:10.1038/290261a0 · Cited by 791
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., & Aaronson, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9193 · Cited by 737
Severe neuropathies in mice with targeted mutations in the ErbB3 receptor
Riethmacher, D., Sonnenberg-Riethmacher, E., Brinkmann, V., Yamaai, T., Lewin, G. R., & Birchmeier, C. (1997) · Nature · doi:10.1038/39593 · Cited by 729
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., & Shoyab, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1746 · Cited by 713
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002) · Nature Medicine · doi:10.1038/nm762 · Cited by 701
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678 · cited 1×
“Somatic mutations within the HER2 kinase domain have been described in a small subset of lung cancers, predominantly in Asian populations, and very rarely in gastric, colorectal and breast cancers (Figure 1, region D) (Stephens et al., 2004; Shigematsu et al., 2005; Lee et al., 2006).”
BackgroundErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 643
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Hudziak, R. M., Schlessinger, J., & Ullrich, A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7159 · Cited by 625
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini
Muthuswamy, S. K., Li, D., Lelievre, S., Bissell, M. J., & Brugge, J. S. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-785 · Cited by 554
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., Hortobagyi, G. N., Yu, D., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.027 · Cited by 537
Schechter, A. L., Hung, M.-C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U., Ullrich, A., & Coussens, L. (1985) · Science · doi:10.1126/science.2992090 · Cited by 518
Wang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 470
Erickson, S. L., O’Shea, K. S., Ghaboosi, N., Loverro, L., Frantz, G., Bauer, M., Lu, L. H., & Moore, M. W. (1997) · Development · doi:10.1242/dev.124.24.4999 · Cited by 467
β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis
Guo, W., Pylayeva, Y., Pepe, A., Yoshioka, T., Muller, W. J., Inghirami, G., & Giancotti, F. G. (2006) · Cell · doi:10.1016/j.cell.2006.05.047 · Cited by 455
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
OSTEOGENESIS IMPERFECTA IS LINKED TO BOTH TYPE I COLLAGEN STRUCTURAL GENES
Sykes, B., Wordsworth, P., Ogilvie, D., Anderson, J., & Jones, N. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91609-0 · Cited by 444
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989) · Nature · doi:10.1038/339230a0 · Cited by 423
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Venter, D., Kumar, S., Tuzi, N., & Gullick, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92736-x · Cited by 404
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
Bouchard, L., Lamarre, L., Tremblay, P. J., & Jolicoeur, P. (1989) · Cell · doi:10.1016/0092-8674(89)90331-0 · Cited by 393
Muthuswamy, S. K., Gilman, M., & Brugge, J. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6845 · Cited by 363
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Ottenhoff-Kalff, A. E., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., & Staal, G. E. J. (1992) · PubMed · Cited by 348
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Britsch, S., Li, L., Kirchhoff, S., Theuring, F., Brinkmann, V., Birchmeier, C., & Riethmacher, D. (1998) · Genes & Development · doi:10.1101/gad.12.12.1825 · Cited by 344
Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V.-M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1061 · Cited by 339
Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L. A., Ewend, M. G., Glas, A. M., Perou, C. M., & van't Veer, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2553 · Cited by 332
A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor
Sibilia, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.719 · Cited by 325
Morris, J. K., Lin, W., Hauser, C., Marchuk, Y., Getman, D., & Lee, K.-F. (1999) · Neuron · doi:10.1016/s0896-6273(00)80779-5 · Cited by 322
Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0250 · Cited by 321
Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer
Subbaramaiah, K., Norton, L., Gerald, W., & Dannenberg, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111415200 · Cited by 317
Zhou, X., Tan, M., Stone Hawthorne, V., Klos, K. S., Lan, K.-H., Yang, Y., Yang, W., Smith, T. L., Shi, D., & Yu, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0112 · Cited by 312
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor
Borg, J.-P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adélaïde, J., Margolis, B., & Birnbaum, D. (2000) · Nature Cell Biology · doi:10.1038/35017038 · Cited by 311
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
A putative molecular-activation switch in the transmembrane domain of erbB2
Fleishman, S. J., Schlessinger, J., & Ben-Tal, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252640799 · Cited by 262
Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4827 · Cited by 258
The epidermal growth factor receptor family
Bazley, L. A., & Gullick, W. J. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01032 · Cited by 250
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, A., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 246
Aranda, V., Haire, T., Nolan, M. E., Calarco, J. P., Rosenberg, A. Z., Fawcett, J. P., Pawson, T., & Muthuswamy, S. K. (2006) · Nature Cell Biology · doi:10.1038/ncb1485 · Cited by 243
Expression of the ERBB3 gene product in breast cancer
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.420 · Cited by 234
Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., & Muller, W. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3444 · Cited by 230
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy, S. K., Siegel, P. M., Dankort, D. L., Webster, M. A., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.735 · Cited by 228
Fedi, P., Pierce, J. H., di Fiore, P. P., & Kraus, M. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.492 · Cited by 228
Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0976 · Cited by 228
Carlsson, J., Nordgren, H., Sjöström, J., Wester, K., Villman, K., Bengtsson, N. O., Ostenstad, B., Lundqvist, H., & Blomqvist, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601881 · Cited by 225
Seton-Rogers, S. E., Lu, Y., Hines, L. M., Koundinya, M., LaBaer, J., Muthuswamy, S. K., & Brugge, J. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308090100 · Cited by 225
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., & Kumar, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202307 · Cited by 222
Real, F. X., Rettig, W. J., Chesa, P. G., Melamed, M. R., Old, L. J., & Mendelsohn, J. M. (1986) · PubMed · Cited by 216
Protein-Tyrosine Phosphatase 1B Is Required for HER2/Neu–Induced Breast Cancer
Bentires-Alj, M., & Neel, B. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4610 · Cited by 216
Kauraniemi, P., Barlund, M. T., Monni, O. M., & Kallioniemi, A. H. (2001) · PubMed · Cited by 214
Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.
Siegel, P. M., Dankort, D. L., Hardy, W. R., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7068 · Cited by 213
PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
Paez, J., & Sellers, W. R. (2003) · PubMed · Cited by 213
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink, A. E. G., Busse, D., Flanagan, W. M., Yakes, F. M., & Arteaga, C. L. (2001) · PubMed · Cited by 207
Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency
Waterman, H., Sabanai, I., Geiger, B., & Yarden, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13819 · Cited by 207
ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 205
α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines
Falcioni, R., Antonini, A., Nisticò, P., Stefano, S. D., Crescenzi, M., Natali, P. G., & Sacchi, A. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3695 · Cited by 202
Carraway, K. L., Rossi, E. A., Komatsu, M., Price-Schiavi, S. A., Huang, D., Guy, P. M., Carvajal, M. E., Fregien, N., Carraway, C. A. C., & Carraway, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5263 · Cited by 196
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
Liu, E., Thor, A. D., He, M., Barcos, M. P., Ljung, B., & Benz, C. C. (1992) · PubMed · Cited by 193
Tanner, M., Tirkkonen, M., Kallioniemi, A. H., Isola, J., Kuukasjärvi, T., Collins, C. C., Kowbel, D., Guan, X., Trent, J. M., Gray, J. W., et al. (1996) · PubMed · Cited by 187
Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P., & Aaronson, S. A. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5570 · Cited by 186
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
Belsches-Jablonski, A. P., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204205 · Cited by 185
Wang, Z., Zhang, L., Yeung, T. K., & Chen, X. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.5.1621 · Cited by 181
Paez, J., & Sellers, W. R. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_6 · Cited by 180
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300477200 · Cited by 179
Tokunaga, E., Kimura, Y., Oki, E., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., Baba, H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21358 · Cited by 177
Hicks, D. G., & Tubbs, R. R. (2005) · Human Pathology · doi:10.1016/j.humpath.2004.11.010 · Cited by 173
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.
Chazin, V. R., Kaleko, M., Miller, A. D., & Slamon, D. J. (1992) · PubMed · Cited by 170
SIERKE, S. L., CHENG, K., KIM, H.-H., & KOLAND, J. G. (1997) · Biochemical Journal · doi:10.1042/bj3220757 · Cited by 168
Howe, L. R., Chang, S.-H., Tolle, K. C., Dillon, R., Young, L. J. T., Cardiff, R. D., Newman, R. A., Yang, P., Thaler, H. T., Muller, W. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1524 · Cited by 165
Role of exon-16-deleted HER2 in breast carcinomas
Castiglioni, F., Tagliabue, E., Campiglio, M., Pupa, S. M., Balsari, A., & Ménard, S. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01047 · Cited by 165
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface
Berger, M. B., Mendrola, J. M., & Lemmon, M. A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.014 · Cited by 164
Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor
Hellyer, N. J., Kim, M.-S., & Koland, J. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102079200 · Cited by 156
Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
Beerli, R. R., Wels, W. S., & Hynes, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51027-4 · Cited by 155
Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer
Kauraniemi, P., & Kallioniemi, A. H. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01147 · Cited by 152
Gambaletta, D., Marchetti, A., Benedetti, L., Mercurio, A. M., Sacchi, A., & Falcioni, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10604 · Cited by 152
Xie, W., Chow, L. T., Paterson, A. J., Chin, E., & Kudlow, J. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202673 · Cited by 148
SAITOU, M., Goto, M., Horinouchi, M., Tamada, S., Nagata, K., Hamada, T., Osako, M., Takao, S., Batra, S. K., Aikou, T., et al. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.023572 · Cited by 145
Goueli, B. S., & Janknecht, R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.25-35.2004 · Cited by 144
Xie, W., Paterson, A. J., Chin, E., Nabell, L. M., & Kudlow, J. E. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.12.0019 · Cited by 143
Faltus, T., Yuan, J., Zimmer, B., Krämer, A., Loibl, S., Kaufmann, M., & Strebhardt, K. (2004) · Neoplasia · doi:10.1593/neo.04313 · Cited by 140
A novel splice variant ofHER2 with increased transformation activity
Kwong, K. Y., & Hung, M. (1998) · Molecular Carcinogenesis · Cited by 139
Choudhury, A., Charo, J., Parapuram, S. K., Hunt, R. C., Hunt, D. M., Seliger, B., & Kiessling, R. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11497 · Cited by 139
Donovan, J. C. H., Milic, A., & Slingerland, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106448200 · Cited by 137
Xie, Y., & Hung, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2368 · Cited by 134
Benlimame, N., He, Q., Su, J., Xiao, D., Xu, Y., Loignon, M., Schlaepfer, D. D., & Alaoui‐Jamali, M. A. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504124 · Cited by 134
Amundadottir, L. T., & Leder, P. (1998) · Oncogene · doi:10.1038/sj.onc.1201829 · Cited by 133
The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis
Shepherd, T. G., Kockeritz, L. K., Szrajber, M. R., Muller, W. J., & Hassell, J. A. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00536-x · Cited by 133
Siegel, P. M., & Muller, W. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.8878 · Cited by 132
Mimura, K., Kono, K., Hanawa, M., Mitsui, F., Sugai, H., Miyagawa, N., Ooi, A., & Fujii, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602499 · Cited by 127
Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125 · cited 2×
“In this model, mouse mammary tumors are induced by overexpression of the human HER2 cDNA, which does not have a DHER2 transcriptional by product associated with it (Finkle et al., 2004).”
BackgroundLi, Y. M., Zhou, B. P., Deng, J., Pan, Y., Hay, N., & Hung, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1284 · Cited by 124
Yang, H.-Y., Zhou, B. P., Hung, M., & Lee, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000147200 · Cited by 122
Park, K., Han, S., Kim, H. J., Kim, J., & Shin, E. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02403.x · Cited by 122
Acetylation-Mediated Transcriptional Activation of the ETS Protein ER81 by p300, P/CAF, and HER2/Neu
Goel, A., & Janknecht, R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6243-6254.2003 · Cited by 121
Tan, M., Li, P., Klos, K. S., Lü, J., Lan, K., Nagata, Y., Fang, D., Jing, T., & Yu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2353 · Cited by 118
Muthuswamy, S. K., & Wj, M. (1995) · PubMed · Cited by 118
Lohrisch, C. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90103-4 · Cited by 113
The epidermal growth factor system in caenorhabditis elegans
Moghal, N., & Sternberg, P. W. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00097-6 · Cited by 113
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function
Ishizawar, R. C., Miyake, T., & Parsons, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210138 · Cited by 107
neu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J., & Perkins, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3155 · Cited by 106
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein
Kim, H., Vijapurkar, U., Hellyer, N. J., Bravo, D., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3340189 · Cited by 106
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner, D. B., Kokai, Y., Wada, T., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989) · PubMed · Cited by 105
Colomer, R., Lupu, R., Bacus, S. S., & Gelmann, E. P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.405 · Cited by 99
Khan, A. J., King, B. L., Smith, B. D., et al. (2002) · PubMed · Cited by 98
Ignatoski, K. M. W., Maehama, T., Markwart, S. M., Dixon, J. E., Livant, D. L., & Ethier, S. P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0979 · Cited by 95
Kauraniemi, P., Kuukasjärvi, T., Sauter, G., & Kallioniemi, A. H. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63556-0 · Cited by 91
Funes, M., Miller, J. K., Lai, C., Carraway, K. L., & Sweeney, C. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603225200 · Cited by 88
Kiguchi, K., Bol, D. K., Carbajal, S., Beltrán, L., Moats, S., Chan, K. S., Jorcano, J. L., & DiGiovanni, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203778 · Cited by 85
Heregulin and HER2 signaling selectively activates c‐Src phosphorylation at tyrosine 215
Vadlamudi, R. K., Şahin, A. A., Adam, L., Wang, R., & Kumar, R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00404-6 · Cited by 84
Palau, V. E., Carraway, C. A. C., Salas, P. J. I., & Carraway, K. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303220200 · Cited by 82
Janes, P. W., Lackmann, M., Church, W. B., Sanderson, G. M., Sutherland, R. L., & Daly, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8490 · Cited by 81
Spangenberg, C., Lausch, E. U., Trost, T. M., Prawitt, D., May, A., Keppler, R., Fees, S. A., Reutzel, D., Bell, C., Schmitt, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2823 · Cited by 79
Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3
Horan, T. P., Wen, J., Arakawa, T., Liu, N., Brankow, D. W., Hu, S., Ratzkin, B. J., & Philo, J. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24604 · Cited by 78
Muthuswamy, S. K., & Wj, M. (1995) · PubMed · Cited by 78
Mano, M. S., Rosa, D. D., de Azambuja, E., Ismael, G., & Durbecq, V. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.10.001 · Cited by 76
Wilson, G., Cramer, A., Welman, A., Knox, F., Swindell, R., Kawakatsu, H., Clarke, R. B., Dive, C., & Bundred, N. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603444 · Cited by 74
Ram, T. G., & Ethier, S. P. (1996) · PubMed · Cited by 73
Polar Expression of ErbB-2/HER2 in Epithelia
Shelly, M., Mosesson, Y., Citri, A., Lavi, S., Zwang, Y., Melamed‐Book, N., Aroeti, B., & Yarden, Y. (2003) · Developmental Cell · doi:10.1016/j.devcel.2003.08.001 · Cited by 72
Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth
Andrechek, E. R., White, D., & Muller, W. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208230 · Cited by 72
HER-2/neu Is Rate-limiting for Ovarian Cancer Growth
Juhl, H. H., Downing, S. G., Wellstein, A., & Czubayko, F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29482 · Cited by 70
Timms, J. F., White, S. L., O’Hare, M. J., & Waterfield, M. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205847 · Cited by 70
Kim, H. L., Chan, R., Dankort, D. L., Zuo, D., Naujokas, M. A., Park, M., & Muller, W. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208898 · Cited by 69
Genetic alterations in ERBB2-amplified breast carcinomas.
Isola, J. J., Chu, L. W., DeVries, S., Matsumura, K., Chew, K., Ljung, B., & Waldman, F. M. (1999) · PubMed · Cited by 69
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma
Tsutsumida, H., Goto, M., Kitajima, S., Kubota, I., Hirotsu, Y., Wakimoto, J., Batra, S. K., Imai, K., & Yonezawa, S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.10.013 · Cited by 67
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms
Hendriks, B. S., Wiley, H. S., & Lauffenburger, D. A. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)74696-7 · Cited by 63
Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity
Xu, W., Yuan, X., Beebe, K. E., Xiang, Z., & Neckers, L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00899-06 · Cited by 63
MLN64 and MENTHO, two mediators of endosomal cholesterol transport
Alpy, F., & Tomasetto, C. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340343 · Cited by 62
Bowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
Zhan, L., Xiang, B., & Muthuswamy, S. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4081 · Cited by 60
Li, Z., Szabolcs, M. J., Terwilliger, J. D., & Efstratiadis, A. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi324 · Cited by 60
Reissig, D., Clement, J. H., Sänger, J., Berndt, A., Kosmehl, H., & Böhmer, F. (2001) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320000197 · Cited by 56
Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Waltersson, M. A., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6457-4 · Cited by 52
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis
Yang, H.-Y., Shao, R., Hung, M., & Lee, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204472 · Cited by 52
Hodgson, J. G., Malek, T. B., Bornstein, S., Hariono, S., Ginzinger, D. G., Muller, W. J., & Gray, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0755 · Cited by 52
Correlation of p27 protein expression with HER‐2/neu expression in breast cancer
Newman, L. A., Xia, W., Yang, H.-Y., Sahin, A., Bondy, M. L., Lukmanji, F., Hung, M., & Lee, M. (2001) · Molecular Carcinogenesis · doi:10.1002/mc.1025 · Cited by 49
C-Src Activation by ErbB2 Leads to Attachment-Independent Growth of Human Breast Epithelial Cells
Sheffield, L. G. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9214 · Cited by 49
Amplification and expression of genes from the 17q11∼q12 amplicon in breast cancer cells
Luoh, S. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00657-4 · Cited by 49
Vijapurkar, U., Kim, M.-S., & Koland, J. G. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00040-x · Cited by 49
Sliwkowski, M. X. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb0303-158 · Cited by 48
The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer
Yang, C., Ionescu-Tiba, V., Burns, K. L., Gadd, M. A., Zukerberg, L. R., Louis, D. N., Sgroi, D. C., & Schmidt, E. V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63190-2 · Cited by 48
Ritland, S. R., Rowse, G. J., Chang, Y., & Gendler, S. J. (1997) · PubMed · Cited by 47
Brandt, R., Wong, A. M.-L., & Hynes, N. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204709 · Cited by 44
Schiffer, I. B., Gebhard, S., Heimerdinger, C. K., Heling, A., Hast, J., Wollscheid, U., Seliger, B., Tanner, B., Gilbert, S., Beckers, T., et al. (2003) · PubMed · Cited by 42
Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase
Hynes, N. E., & Lane, H. A. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009528918064 · Cited by 38
Biology of the Epidermal Growth Factor Receptor Family
Barnes, C. J., & Kumar, R. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_1 · Cited by 37
Weinstein, E. J., Kitsberg, D., & Leder, P. (2000) · Molecular Medicine · doi:10.1007/bf03401930 · Cited by 35
Xie, W., Wu, X., Chow, L. T., Chin, E., Paterson, A. J., & Kudlow, J. E. (1998) · PubMed · Cited by 35
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
Loureiro, R. M. B., Maharaj, A. S. R., Dankort, D. L., Muller, W. J., & D'Amore, P. A. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.053 · Cited by 30
Messerle, K., Schlegel, J., Hynes, N. E., & Groner, B. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90029-9 · Cited by 28
Goodearl, A. D. J., Viehöver, A., & Vartanian, T. K. (2001) · Developmental Neuroscience · doi:10.1159/000048693 · Cited by 15
Cited by
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Yersal, O. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.412 · Cited by 1,156
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Metadata
- Authors
- Moasser, M. M.
- Venue
- Oncogene
- Published
- 2007-04-30
- Volume
- 26
- Issue
- 45
- Pages
- 6469-6487
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2056579307
- Cited by
- 1,219
- References
- 201
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.